Exosome therapeutics developer Codiak BioSciences, exploiting technology developed by researchers at the universities of Gothenburg and Texas, is eyeing up to $86.3m in an IPO.
Codiak BioSciences, a US-based exosome therapeutics developer, has filed to raise up to $86.3m in an initial public offering.
Founded in 2015, Codiak is developing exosome therapeutics to treat a range of conditions, including cancer, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders and rare diseases.
The company’s therapeutics are created by engineering exosomes, extracellular vesicles that are produced by nearly all cells in the human body and which can change the biological function of cells.
…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
